Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients

Bone Marrow Transplantation volume 45, pages 269–275 (2010)Cite this article

Abstract

This report describes the first investigational use of plerixafor in Europe and the determination of tumor cell mobilization by polymerase chain-reaction after plerixafor treatment in a subset of patients with multiple myeloma (MM). Thirty-five patients (31 MM and 4 NHL) received granulocyte colony-stimulating factor (G-CSF) (10 μg/kg) each morning for 4 days. Starting the evening of Day 4, patients recieved plerixafor 0.24 mg/kg. Apheresis was initiated 10–11 h later, in the morning of Day 5. This regimen of G-CSF treatment each morning before apheresis and plerixafor treatment in the evening was repeated for up to 5 consecutive days. Mobilization with plerixafor and G-CSF resulted in a median 2.6-fold increase in peripheral blood (PB) CD34+ cell count compared with before plerixafor treatment. All patients collected ⩾2 × 106 CD34+ cells/kg and 32 of 35 patients collected ⩾5 × 106 CD34+ cells/kg. After plerixafor treatment, 3 of 7 patients had a small increase and 4 of 7 patients had a small decrease in PB tumor cells. No G-CSF was given post transplant. The median number of days to polymorphonuclear leukocyte and platelet engraftment was 14.0 and 11.0, respectively. There were no reports of graft failure. Plerixafor was generally well tolerated. Mobilization of PB CD34+ cells was consistent with previous clinical trials. The addition of plerixafor did not significantly increase the relative number of PB MM tumor cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Fruehauf S, Seeger T . New strategies for mobilization of hematopoietic stem cells. Future Oncol 2005; 1: 375–383.

    Article  CAS  PubMed  Google Scholar 

  2. Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 743–750.

    Article  CAS  PubMed  Google Scholar 

  3. Fruehauf S, Seggewiss R . It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. Br J Haematol 2003; 122: 360–375.

    Article  CAS  PubMed  Google Scholar 

  4. Liles W, Rodger E, Broxmeyer H, Dehner C, Badel K, Calandra G et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295–300.

    Article  CAS  PubMed  Google Scholar 

  5. Broxmeyer H, Orschell C, Clapp D, Hangoc G, Cooper S, Plett P et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307–1318.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Fruehauf S, Seeger T, Maier P, Li L, Weinhardt S, Laufs S et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol 2006; 34: 1052–1059.

    Article  CAS  PubMed  Google Scholar 

  7. Cremer FW, Kiel K, Wallmeier M, Goldschmidt H, Moos M . A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol 1997; 8: 633–636.

    Article  CAS  PubMed  Google Scholar 

  8. Flomenberg N, Devine S, Dipersio J, Liesveld J, McCarty J, Rowley S et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  PubMed  Google Scholar 

  9. Jillella A, Ustun C . What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev 2004; 13: 598–606.

    Article  PubMed  Google Scholar 

  10. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596.

    CAS  PubMed  Google Scholar 

  11. Gazitt Y, Freytes CO, Callander N, Tsai T-W, Alsina M, Anderson J et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother 1999; 8: 173–183.

    Article  CAS  PubMed  Google Scholar 

  12. Flomenberg N, Comenzo R, Badel K, Calandra G . Single agent AMD3100 mobilization of peripheral blood progenitor cells for autologous transplantation in patients with multiple myeloma (MM). ASH Annual Meeting Abstracts 2006; 108: 3381.

    Google Scholar 

  13. Linch D, Donald W, Milligan D, Winfield S, Kelsey S, Johnson T et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997; 99: 933–938.

    Article  CAS  PubMed  Google Scholar 

  14. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH . Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451–457.

    Article  CAS  PubMed  Google Scholar 

  15. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2007; 41: 331–338.

    Article  PubMed  Google Scholar 

  16. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992; 80: 1818–1824.

    CAS  PubMed  Google Scholar 

  17. Haas R, Moos M, Karcher A, Mohle R, Witt B, Goldschmidt H et al. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 1685–1692.

    Article  CAS  PubMed  Google Scholar 

  18. Pantel K, Brakenhoff RH, Brandt B . Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Rev 2008; 8: 329–340.

    CAS  Google Scholar 

  19. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007; 117: 1305–1313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Anagnostopoulos A, Aleman A, Yang Y, Donato M, Weber D, Champlin R et al. Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant 2004; 33: 623–628.

    Article  CAS  PubMed  Google Scholar 

  21. Kopp HG, Yildirim S, Weisel KC, Kanz L, Vogel W . Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol 2008; 135: 637–642.

    Article  PubMed  Google Scholar 

  22. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR . Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant 1997; 19: 337–342.

    Article  CAS  PubMed  Google Scholar 

  23. Blystad AK, Delabie J, Kvaloy S, Holte H, Valerhaugen H, Ikonomou I et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004; 125: 605–612.

    Article  CAS  PubMed  Google Scholar 

  24. Ho J, Yang L, Banihashemi B, Martin L, Halpenny M, Atkins H et al. Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2009; 43: 223–228.

    Article  CAS  PubMed  Google Scholar 

  25. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–3779.

    Article  CAS  PubMed  Google Scholar 

  26. Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007; 92: 1083–1090.

    Article  PubMed  Google Scholar 

  27. DiPersio J, Stadtmauer EA, Nademanee AP, Stiff P, Micallef I, Angell J et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs. G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood (ASH Annual Meeting Abstracts) 2007; 110: 445.

    Google Scholar 

  28. DiPersio JF, Micallef I, Stiff PJ, Bolwell BJ, Maziarz RT, Angell J et al. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs. placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Annual Meeting Abstracts 2007; 110: 601.

    Google Scholar 

  29. DiPersio JF, Micallef INM, Stiff PJ, Bolwell BJ, Maziarz RT, Bridger G et al. Months report from the phase 3 study of plerixafor+G-CSF vs. placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood (ASH Annual Meeting Abstracts) 2008; 112: 1136.

    Google Scholar 

  30. DiPersio JF, Stadtmauer EA, Nademanee AP, Micallef INM, Stiff PJ, Bridger G et al. 12 months report from a phase 3 study of plerixafor+G-CSF vs. placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2008; 112: 3312.

    Google Scholar 

  31. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Funding Support: This study was formerly supported wholly by AnorMED, Inc., now Genzyme Corporation, Cambridge, MA, USA.

Author information

Authors and Affiliations

  1. Center for Tumor Diagnostics and Therapy, Paracelsus Klinik, Osnabrueck, Germany

    S Fruehauf & J Topaly

  2. Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany

    S Fruehauf, J Topaly, H Goldschmidt, A D Ho, S Müller & M Moos

  3. Department of Internal Medicine I, Division of Hematology and Oncology, Carl Gustav Carus University, Dresden, Germany

    G Ehninger

  4. Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany

    K Hübel

  5. Formerly AnorMED Inc., now Genzyme Corporation, Cambridge, MA, USA

    K Badel & G Calandra

Authors
  1. S Fruehauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Ehninger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Hübel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Topaly
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A D Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Moos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Badel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Calandra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Fruehauf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fruehauf, S., Ehninger, G., Hübel, K. et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 45, 269–275 (2010). https://doi.org/10.1038/bmt.2009.142

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.142

Keywords

This article is cited by

Search

Advanced search

Quick links